Meet the Faces of Zen: Elanco's Zenrelia™ (ilunocitinib tablets) Helps Allergic Dogs Get Back to Normal

• Hunter, Trooper, Scrappy and Buckaroo find zen by using Zenrelia
• Newly published study in a leading peer-reviewed, international journal, Veterinary Dermatology, compares clinical outcomes between Zenrelia and Apoquel® (oclacitinib tablet)

GREENFIELD, Ind., Jan. 27, 2025 /PRNewswire/ -- Scratching, rubbing, chewing, licking. All signs of an irritated, itchy dog. With approximately 17 million U.S. dogs suffering from allergic skin disease, including atopic dermatitis, food allergies or flea sensitivity,^i,ii these are the sounds too many pet parents and veterinarians hear. Today, Elanco Animal Health Incorporated (NYSE: ELAN), is introducing some of the first allergic dogs who have found zen and gotten back to normal by using Zenrelia. Zenrelia, which was approved by the U.S. Food and Drug Administration (FDA) and launched in September 2024, is a highly effective, convenient and safe once-daily oral JAK inhibitor for control of pruritus (itching) associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.